Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Abstract Simultaneous blockade of immune checkpoint molecules and co-stimulation of the TNF receptor superfamily (TNFRSF) is predicted to improve overall survival in human cancer. TNFRSF co-stimulation depends upon coordinated antigen recognition through the T cell receptor followed by homotrimeriza...

Full description

Bibliographic Details
Main Authors: George Fromm, Suresh de Silva, Kellsey Johannes, Arpita Patel, Josiah C. Hornblower, Taylor H. Schreiber
Format: Article
Language:English
Published: BMJ Publishing Group 2018-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Cancer immunotherapy
Checkpoint
Costimulator
OX40
PD1
Online Access:http://link.springer.com/article/10.1186/s40425-018-0454-3

Internet

http://link.springer.com/article/10.1186/s40425-018-0454-3

Similar Items